Novo Nordisk A/S has published its latest weekly update on its ongoing Safe Harbour share repurchase programme, disclosing transactions made between 9 and 13 November 2026. The Danish healthcare giant bought 1,130,000 B shares across five trading days, bringing total accumulated purchases under the current programme to 28,975,000 shares at a combined value of DKK 8,318,073,280. The update forms part of a broader repurchase initiative of up to DKK 15 billion authorised over a 12-month period beginning 4 February 2026, and investors may be watching progress against that ceiling closely.

Key Points

  • Novo Nordisk A/S – Class B (0QIU), listed on Nasdaq Copenhagen as Novo-B and on the New York Stock Exchange as NVO
  • Novo Nordisk repurchased 1,130,000 B shares between 9 and 13 November 2026 under its Safe Harbour programme initiated on 6 May 2026
  • As of 13 November 2026, total repurchases since 4 February 2026 stand at 43,734,179 B shares at an average price of DKK 277.08, equalling DKK 12,118,073,269
  • Investors should watch the remaining headroom against the DKK 15 billion programme ceiling and the 1 February 2027 programme end date

Weekly B Share Buyback Transactions from 9 to 13 November 2026

Across the five trading sessions covered by this announcement, Novo Nordisk purchased 225,000 or 230,000 B shares each day. On 9 November 2026, the company bought 230,000 shares at an average price of DKK 273.19, for a transaction value of DKK 62,833,589. Daily purchases of 225,000 shares followed on each subsequent session, with average prices ranging from DKK 272.61 on 11 November to DKK 276.39 on 12 November 2026. The combined value of these five daily transactions was DKK 310,059,558, as reflected in the movement from the previously accumulated total to the newly reported figure of DKK 8,318,073,280.

Novo Nordisk's DKK 15 Billion Programme Reaches DKK 12.1 Billion Since February 2026

The broader repurchase programme, which began on 4 February 2026, authorises Novo Nordisk to buy back up to DKK 15 billion of B shares within twelve months. As of 13 November 2026, the company has deployed DKK 12,118,073,269 of that budget, repurchasing 43,734,179 B shares at an average price of DKK 277.08 per share. The sub-programme initiated on 6 May 2026 carries an upper limit of DKK 11,200,000,010.45 and runs until 1 February 2027. All transactions are conducted in compliance with Article 5 of the EU Market Abuse Regulation and the Commission Delegated Regulation Safe Harbour Rules.

Treasury Share Position and Incentive Programme Transfers Disclosed

Following the transactions reported in this update, Novo Nordisk holds a total of 57,645,131 B shares as treasury shares, representing 1.3% of the company's total share capital. The total number of A and B shares in issue, including treasury shares, stands at 4,465,000,000. The company separately disclosed that incentive programme-related transactions resulted in a net transfer of 129,745 B shares from Novo Nordisk between 9 and 13 November 2026; these shares were explicitly stated to fall outside the Safe Harbour repurchase programme. Full transaction-level detail is published on novonordisk.com.

Global Healthcare Operations Underpin Novo Nordisk's Capital Return Activity

Novo Nordisk is a global healthcare company headquartered in Bagsværd, Denmark, employing over 66,500 people worldwide. The company develops treatments and support products aimed at helping patients manage chronic conditions, and has operated for over a century. Its B shares trade on Nasdaq Copenhagen under the ticker Novo-B, while its American Depositary Receipts are listed on the New York Stock Exchange under the symbol NVO. The scale of the ongoing buyback programme reflects the company's capital allocation strategy, though investors will note that the remaining DKK 15 billion authorisation leaves limited headroom before the February 2027 deadline.